CN113633657B - 一种提高机体抗疲劳、耐缺氧、耐热和耐寒能力的药物组合物及其应用 - Google Patents
一种提高机体抗疲劳、耐缺氧、耐热和耐寒能力的药物组合物及其应用 Download PDFInfo
- Publication number
- CN113633657B CN113633657B CN202110500385.8A CN202110500385A CN113633657B CN 113633657 B CN113633657 B CN 113633657B CN 202110500385 A CN202110500385 A CN 202110500385A CN 113633657 B CN113633657 B CN 113633657B
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- resistant
- fatigue
- polysaccharide
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 206010021143 Hypoxia Diseases 0.000 title abstract description 13
- 230000002929 anti-fatigue Effects 0.000 title abstract description 13
- 230000007954 hypoxia Effects 0.000 title abstract description 11
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 claims abstract description 32
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 claims abstract description 32
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 claims abstract description 32
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 20
- 241001465754 Metazoa Species 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 abstract description 16
- 229920001282 polysaccharide Polymers 0.000 abstract description 16
- 239000005017 polysaccharide Substances 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 12
- 235000017784 Mespilus germanica Nutrition 0.000 abstract description 8
- 244000182216 Mimusops elengi Species 0.000 abstract description 8
- 235000000560 Mimusops elengi Nutrition 0.000 abstract description 8
- 235000007837 Vangueria infausta Nutrition 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 26
- 244000241838 Lycium barbarum Species 0.000 description 13
- 235000015459 Lycium barbarum Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 235000015468 Lycium chinense Nutrition 0.000 description 11
- 206010016256 fatigue Diseases 0.000 description 11
- 229940089161 ginsenoside Drugs 0.000 description 10
- 229930182494 ginsenoside Natural products 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ADNBOFQFSCPWBA-RJMJUYIDSA-N [Na].O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound [Na].O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O ADNBOFQFSCPWBA-RJMJUYIDSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种提高机体抗疲劳、耐缺氧、耐热和耐寒能力的药物组合物及其应用，所述药物组合物由人参皂苷Rh2与枸杞多糖组成，所述人参皂苷Rh2与枸杞多糖的重量比为1:30～1:1500。本发明通过药效学研究发现一定比例组合范围内的人参皂苷Rh2和枸杞(枸杞子)多糖的组合物具有比较明显的抗疲劳以及提高耐缺氧、耐寒和耐热能力的作用，且较人参皂苷Rh2或枸杞多糖单用具有协同增效的作用。本发明所涉及组合物配以适当的药用和食用辅料，可应用于医药和保健品种。
Description
技术领域
本发明涉及药物技术领域，具体地说，涉及人参皂苷Rh2和枸杞(枸杞子)多糖的组合物在抗疲劳以及提高耐缺氧、耐寒和耐热功能上的应用。较单独与人参皂苷Rh2和枸杞多糖相比，具有协同增效的作用。
背景技术
人们在日常生活和生产过程中不可避免地遇到工作能力下降的现象，我们将这种现象称为疲劳，在1982年第5届国际运动生物化学会议上人们将运动型疲劳定义为：“机体的生理过程不能维持其机能在一特定水平和/或不能维持其预定的运动强度”[Allen DG,Lamb GD,Westerblad H.Skeletal Muscle Fatigue:Cellular Mechanisms,Physiological Reviews,2008,88:287-332.]。随着社会竞争的日趋激烈，生活节奏的加快，工作压力的增大，疲劳症的发病率呈现日益增高的趋势。疲劳虽然不像癌症、心血管疾病那样直接危及到人们的生命，但可严重影响人类的生活质量。长期的疲劳会使机体处于一种亚健康的状态，这种亚健康主要表现为疲劳、活力减退、免疫力降低等[Yu-Xiang Yan,You-Qin Liu,Man Li et al,Development and Evaluation of a Questionnaire forMeasuring Suboptimal Health Status in Urban Chinese,J Epidemiol.2009；19:333-341.]。目前缓解疲劳的方法大多通过睡眠、休养进行机体调整，另一方面依靠外在物质的调整提高身体机能。但目前缺乏有效的药物和方法，仅仅通过被动的心理调节或者给予一些提高兴奋度的药物，使绝大多数疲劳程度并没有得到缓解。现代西医药学对这种亚健康状态缺乏有效的治疗手段，而中医药在该方面积累了丰富的经验，显示出独特的优势。
人参自古是滋补强壮的良药，现代研究也显示，人参在抗疲劳中发挥了良好的作用，但是其作用的成分不详。专利200610017063.3公开了人参、咖啡、茶叶组合物的抗疲劳作用。专利200610131959.4公开了人参皂苷Rh2在抗疲劳方面的新用途，且不良反应甚微，是一种理想的抗疲劳药物。
枸杞子系茄科宁夏枸杞的干燥成熟果实，为传统中药，具有滋补强壮、益精气、祛风、壮阳、强筋骨等功能，现代科学研究证明枸杞有效成分为枸杞多糖，具有降血糖、降血脂、提高免疫、抗氧化、抗疲劳等作用。《食疗本草》上记载枸杞具有“坚筋耐劳、陈风，补益筋骨，能益人，去虚劳”的功用。其所含的多糖作为一种天然植物多糖，既具有丰富的生物活性，又无毒副作用[滕俊,袁佳,叶莎莎.枸杞子化学成分及药理作用相关性概述.海峡药学,2014,26:36-37.]，无论在临床应用还是保健类食品开发方面均具有广阔的前景。
而目前未见人参皂苷Rh2和枸杞(枸杞子)多糖联用在提高机体抗疲劳、耐缺氧、耐热和耐寒能力方面的报道。
发明内容
本发明的目的是针对现有技术中的不足，提供一种药物组合物。
本发明的第二个目的是，提供所述药物组合物的用途。
为实现上述目的，本发明采取的技术方案是：
一种药物组合物，所述药物组合物由人参皂苷Rh2与枸杞多糖组成，所述人参皂苷Rh2与枸杞多糖的重量比为1:30～1:1500。
进一步，所述人参皂苷Rh2与枸杞多糖的重量比为1:30～1:40。
进一步，所述人参皂苷Rh2与枸杞多糖的重量比为1:40。
为实现上述第二个目的，本发明采取的技术方案是：
如上任一所述药物组合物在制备抗疲劳的药物中的应用。
进一步，所述药物根据需要加入药物可接受的基质辅料制备成任何药用剂型。
进一步，所述药物的剂型为胶囊、颗粒、片剂、口服液或合剂。
进一步，所述药物可接受的基质辅料包括但不限于：羧甲基纤维素钠、甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠，一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁。
如上任一所述的药物组合物在制备提高动物个体的耐缺氧能力的药物中的应用。
如上任一所述的药物组合物在制备提高动物个体的抗寒能力的药物中的应用。
如上任一所述的药物组合物在制备提高动物个体的抗热能力的药物中的应用。
进一步，所述动物为哺乳动物。
进一步，所述哺乳动物选自人、大鼠、小鼠、猴、狗、兔或猪。
本发明优点在于：
1、本发明的药物组合物是发明人经过大量对比试验筛选的，其中，人参皂苷Rh2虽然有较好的抗疲劳活性，但其在药材中含量较低，且价格昂贵，不适合大剂量使用，而枸杞多糖对抗疲劳作用并不显著。本发明通过人参皂Rh2与枸杞多糖的协同作用，显著降低人参皂Rh2的使用比例，降低药物成本，显著增强药物的抗疲劳活性。
2、本发明的药物组合物可以提高动物个体的耐缺氧、耐寒和耐热能力，且人参皂Rh2与枸杞多糖表现出协同作用。这对提高极端气候条件下动物个体的生存能力具有重要意义。
具体实施方式
下面结合具体实施方式，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解，在阅读了本发明记载的内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。
本发明所用术语“可接受的”，指一个处方组分或活性成分对一般治疗目标的健康没有过分的有害影响。
本发明所用术语“药学上可接受”这里指一种物质，如载体或稀释液，不会使化合物的生物活性或性质消失，且相对无毒，如，给予个体某物质，不会引起不想要的生物影响或以有害的方式与任何其含有的组分相互作用。
实施例1本发明的药物组合物(一)
按重量份配比称取人参皂苷Rh2 1份、枸杞多糖10份，混合均匀。
实施例2本发明的药物组合物(二)
按重量份配比称取人参皂苷Rh2 1份、枸杞多糖20份，混合均匀。
实施例3本发明的药物组合物(三)
按重量份配比称取人参皂苷Rh2 1份、枸杞多糖40份，混合均匀。
实施例4本发明的药物组合物(四)
按重量份配比称取人参皂苷Rh2 2份、枸杞多糖10份，混合均匀。
实施例5本发明的药物组合物(五)
按重量份配比称取人参皂苷Rh2 2份、枸杞多糖20份，混合均匀。
实施例6本发明的药物组合物(六)
按重量份配比称取人参皂苷Rh2 2份、枸杞多糖40份，混合均匀。
实施例7本发明人参皂苷Rh2与枸杞多糖的胶囊剂的制备
人参皂苷Rh2 8克，枸杞多糖1600克，加乳糖羧甲基纤维素钠混匀，过80目筛，加入5％聚维酮K30的70％乙醇溶液适量制备得软材，过40目筛，制粒，装入胶囊，即得胶囊剂。
实施例8本发明人参皂苷Rh2与枸杞多糖的片剂的制备
人参皂苷Rh2 8克，枸杞多糖1600克，加乳糖羧甲基纤维素钠混匀，过80目筛，加入5％聚维酮K30的70％乙醇溶液适量制备得软材，过20目筛，再加入适量的硬脂酸镁，混合均匀，压片，得到片剂。
实施例9本发明人参皂苷Rh2与枸杞多糖的口服液的制备
吐温-80适量，人参皂苷Rh2 8克，枸杞多糖1600克，研磨制成初乳，再加水至4000ml，即得溶液(口服)。
实施例10本发明药物组合物的动物实验
1.材料
1.1实验动物
清洁级小鼠，18-20g，购自第二军医大学动物实验中心。许可证号：SCXK(沪)2013-0003。
1.2药物
人参皂苷Rh2，购自本素医药科技有限公司，含量≥99％。
枸杞多糖，购自本素医药科技有限公司，含量≥35％。
2.方法
2.1动物分组与给药
按体重随机分组，每组40只。阴性对照：溶剂对照。给药剂量：人参皂苷Rh2，1mg/Kg，2mg/Kg(R1，R2)；枸杞多糖：10mg/Kg，20mg/Kg，40mg/Kg(LBP-L，LBP-M，LBP-H)。人参皂苷Rh2+枸杞多糖：1mg/Kg+10mg/Kg，1mg/Kg+20mg/Kg，1mg/Kg+40mg/Kg(R1+LBP-L，R1+LBP-M，R1+LBP-H)；人参皂苷Rh2+枸杞多糖：2mg/Kg+10mg/Kg，2mg/Kg+20mg/Kg，2mg/Kg+40mg/Kg(R2+LBP-L，R2+LBP-M，R2+LBP-H)。
药物配制：称取一定量的人参皂苷Rh2，加入少量0.3％CMC-Na，研磨制成混悬液，并用CMC-Na稀释至所需的浓度。在人参皂苷Rh2混悬液中加入枸杞多糖配制成相应浓度的组合物。枸杞多糖分别配制成1，2，4g/L的溶液。给药方法：采用灌胃法每日以不同剂量给小鼠灌胃给药，每日1次，连续给药15天。
2.2常压耐缺氧实验
每组取出10只小鼠，在第15天末次灌胃1h后，放入盛有10g钠石灰的300mL广口瓶中，瓶盖涂以凡士林密封，使之不漏气，记录小鼠存活时间。
2.3负重游泳实验
每组取出10只小鼠，末次灌胃1h后，给小鼠尾部施加5％其自身体质量的铅皮，放置于水深30cm的玻璃游泳箱内游泳，水温保持(25±1)℃，记录小鼠的游泳存活时间。
2.4耐寒实验
每组取出10只小鼠，末次灌胃1h后，分别装入4个铁丝笼中，置于-20℃的冰箱中，以4组小鼠总数中死亡20只为界，记录每组小鼠的死亡数量。
2.5耐热实验
每组取出10只小鼠，末次灌胃1h后，分别装入4个铁丝笼中，置于50℃的烘箱中，以4组小鼠总数中死亡30只为界，记录每组小鼠的死亡数量。
2.6统计学处理
所有实验数据用SPSS11.0统计软件进行数据处理分析，计量资料以均数±标准差表示，各组间比较用t检验，以P＜0.05为差异有统计学意义。
3.结果
表1不同组合物对强迫游泳小鼠和耐缺氧小鼠的影响
注，与空白对照组比较：*:P<0.05；**:P<0.01
表2不同组合物对小鼠耐寒和耐热能力的影响
注，与空白对照组比较：*:P<0.05；**:P<0.01
实验结果如表1及表2所示。结果显示：不同剂量组合的组合物均能延长小鼠的负重游泳时间，延长小鼠的耐缺氧时间，增加小鼠在高寒和高热环境下的存活率，与空白对照组比较，有较明显的统计学意义(P<0.05或P<0.01)。
4.结论
人参皂苷Rh2和枸杞多糖组合物(参杞)具有明显延长小鼠耐缺氧时间，小鼠负重游泳时间的作用及小鼠抗寒冷与高热环境下的存活率，即表现出明显的抗疲劳作用和提高个体对极端环境适应能力的作用。本发明在实验前期还设计了对比试验，在相同给药剂量及相同实验条件下，人参皂苷Rh2与枸杞多糖组合对小鼠抗疲劳以及耐缺氧、耐寒、耐热能力的提高作用显著高于人参皂苷Rh2或枸杞多糖单独给药，说明人参皂苷Rh2与枸杞多糖组合具有显著的协同作用。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员，在不脱离本发明方法的前提下，还可以做出若干改进和补充，这些改进和补充也应视为本发明的保护范围。
Claims (2)
1.一种药物组合物在制备提高动物个体的抗寒能力的药物中的应用，其特征在于，所述药物组合物由人参皂苷Rh2与枸杞多糖组成，所述人参皂苷Rh2与枸杞多糖的重量比为1:30～1:40。
2.根据权利要求1所述的应用，其特征在于，所述人参皂苷Rh2与枸杞多糖的重量比为1:40。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110500385.8A CN113633657B (zh) | 2021-05-08 | 2021-05-08 | 一种提高机体抗疲劳、耐缺氧、耐热和耐寒能力的药物组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110500385.8A CN113633657B (zh) | 2021-05-08 | 2021-05-08 | 一种提高机体抗疲劳、耐缺氧、耐热和耐寒能力的药物组合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113633657A CN113633657A (zh) | 2021-11-12 |
| CN113633657B true CN113633657B (zh) | 2024-03-01 |
Family
ID=78415777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110500385.8A Active CN113633657B (zh) | 2021-05-08 | 2021-05-08 | 一种提高机体抗疲劳、耐缺氧、耐热和耐寒能力的药物组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113633657B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116115696B (zh) * | 2023-04-07 | 2023-12-12 | 中国人民解放军空军军医大学 | 提高机体冷习服能力的中药组合物及其制备方法、用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101502316A (zh) * | 2009-03-11 | 2009-08-12 | 中国科学院武汉植物园 | 一种枸杞多糖的提取方法 |
| CN101612159A (zh) * | 2008-06-23 | 2009-12-30 | 上海药谷药业有限公司 | 化合物20(S)-人参皂苷Rh2在制备抗疲劳药物中的应用 |
| CN101890040A (zh) * | 2010-07-27 | 2010-11-24 | 上海中药创新研究中心 | 一种具有抗疲劳作用的组合物及其应用 |
| CN110237153A (zh) * | 2019-07-29 | 2019-09-17 | 北京本草方源药业集团有限公司 | 一种复合颗粒剂及其制备方法 |
-
2021
- 2021-05-08 CN CN202110500385.8A patent/CN113633657B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612159A (zh) * | 2008-06-23 | 2009-12-30 | 上海药谷药业有限公司 | 化合物20(S)-人参皂苷Rh2在制备抗疲劳药物中的应用 |
| CN101502316A (zh) * | 2009-03-11 | 2009-08-12 | 中国科学院武汉植物园 | 一种枸杞多糖的提取方法 |
| CN101890040A (zh) * | 2010-07-27 | 2010-11-24 | 上海中药创新研究中心 | 一种具有抗疲劳作用的组合物及其应用 |
| CN110237153A (zh) * | 2019-07-29 | 2019-09-17 | 北京本草方源药业集团有限公司 | 一种复合颗粒剂及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| 枸杞多糖对小鼠耐缺氧及抗疲劳能力的影响;盛伟，等;《新乡医学院学报》;第28卷(第3期);298-300 * |
| 梅全喜，主编.《现代中药药理与临床应用手册》.中国中医药出版社,2008,798-799. * |
| 詹益兴，主编.《绿色精细化工——天然产品制造法（第1集）》.科学技术文献出版社,2005,207-208. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113633657A (zh) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101890040B (zh) | 一种具有抗疲劳作用的组合物及其应用 | |
| CN104026446B (zh) | 一种适合于高血糖人群服用的营养代餐粉及其制备方法 | |
| US10485836B2 (en) | Anti-fatigue composition used for increasing endurance performance, and use of the same | |
| CN111035649A (zh) | 一种nmn+glp复配营养补充剂及其制备方法和应用 | |
| CN103355655A (zh) | 一种具有改善营养性贫血功能的组合物及其制备方法 | |
| CN113633657B (zh) | 一种提高机体抗疲劳、耐缺氧、耐热和耐寒能力的药物组合物及其应用 | |
| CN105341893A (zh) | 一种辅助降血糖的组合物及应用 | |
| CN107223981B (zh) | 含大豆多肽阿格拉欣的组合物及其制备方法 | |
| CN105343056A (zh) | 一种治疗或预防肥胖型高血压的口服药物组合物及其用途 | |
| CN108066350B (zh) | 连翘苷、其衍生物、连翘苷与连翘脂素组合物在制备预防、治疗老年痴呆症药物中的应用 | |
| CN104644734A (zh) | 一种治疗ⅱ型糖尿病及其并发症的药物 | |
| CN101152196A (zh) | 三七总皂苷及其单体在制备治疗抑郁症药物中的应用 | |
| CN102225082B (zh) | 一种防治糖尿病及其并发症的药物和其制备方法 | |
| CN101897717B (zh) | 一种治疗糖尿病的中药组合物及用途 | |
| CN112075633A (zh) | 天然提取物和膳食纤维复配的减肥组合物 | |
| CN105616581A (zh) | 一种含有格列吡嗪的治疗糖尿病的药物组合物及其制备方法 | |
| CN1287808C (zh) | 银杏叶提取物组合物 | |
| CN100423773C (zh) | 火麻仁球蛋白在制药中的应用 | |
| CN110269897A (zh) | 一种抗疲劳和改善睡眠的组合物及其用途 | |
| CN109432082B (zh) | 一种防治化学性肝损伤的药物组合物 | |
| KR102615692B1 (ko) | 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물 | |
| CN103860761A (zh) | 一种提高免疫抗疲劳的药物组合物及其制备方法和应用 | |
| US20220054566A1 (en) | Antiviral composition having antiviral activity against coronavirus and variant viruses thereof | |
| CN102327304A (zh) | 一种防治慢性高原病的药物及其制备方法 | |
| CN105561296A (zh) | 一种改善运动性贫血的组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |